{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T02:01:51Z","timestamp":1777168911805,"version":"3.51.4"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T00:00:00Z","timestamp":1329350400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1002380","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T21:50:46Z","timestamp":1329429046000},"page":"e1002380","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":218,"title":["DOGS: Reaction-Driven de novo Design of Bioactive Compounds"],"prefix":"10.1371","volume":"8","author":[{"given":"Markus","family":"Hartenfeller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiko","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Walter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Reisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewgenij","family":"Proschak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Weggen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Stark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisbert","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2012,2,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrd1799","article-title":"Computer-based de novo design of druglike molecules.","volume":"4","author":"G Schneider","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-1-60761-839-3_12","article-title":"De novo drug design.","volume":"672","author":"M Hartenfeller","year":"2011","journal-title":"Methods Mol Biol"},{"key":"ref3","first-page":"365","article-title":"Recent developments in de novo design and scaffold hopping.","volume":"11","author":"H Mauser","year":"2008","journal-title":"Curr Opin Drug Discov Develop"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1517\/17460441.2010.497534","article-title":"De novo design: balancing novelty and confined chemical space.","volume":"5","author":"PS Kutchukian","year":"2010","journal-title":"Expert Opin Drug Discov"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1021\/jm050054p","article-title":"Molecular complexity analysis of de novo designed ligands.","volume":"49","author":"K Boda","year":"2006","journal-title":"J Med Chem"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1747-0285.2008.00672.x","article-title":"Concept of combinatorial de novo design of druglike molecules by particle swarm optimization.","volume":"72","author":"M Hartenfeller","year":"2008","journal-title":"Chem Biol Drug Des"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/ci9000458","article-title":"FOG: Fragment optimized growth algorithm for the de novo generation of molecules occupying druglike chemical space.","volume":"49","author":"PS Kutchukian","year":"2009","journal-title":"J Chem Inf Model"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1021\/ci970429i","article-title":"RECAP - retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry.","volume":"38","author":"XQ Lewell","year":"1998","journal-title":"J Chem Inf Comput Sci"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1023\/A:1008184403558","article-title":"De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks.","volume":"14","author":"G Schneider","year":"2000","journal-title":"J Comput Aided Mol Des"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1002\/1521-3773(20001117)39:22<4130::AID-ANIE4130>3.0.CO;2-E","article-title":"Virtual screening for bioactive molecules by evolutionary de novo design.","volume":"39","author":"G Schneider","year":"2000","journal-title":"Angew Chem Int Ed"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/ci0503560","article-title":"Flux (1): a virtual synthesis scheme for fragment-based de novo design.","volume":"46","author":"U Fechner","year":"2006","journal-title":"J Chem Inf Model"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1021\/ci6005307","article-title":"Flux (2): comparison of molecular mutation and crossover operators for ligand-based de novo design.","volume":"47","author":"U Fechner","year":"2007","journal-title":"J Chem Inf Model"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1021\/jm030809x","article-title":"SYNOPSIS: SYNthesize and OPtimize System In Silico.","volume":"46","author":"HM Vinkers","year":"2003","journal-title":"J Med Chem"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4155\/fmc.11.8","article-title":"Reaction-driven <italic>de novo<\/italic> design: from virtual compound assembly <italic>via<\/italic> target profile prediction to chemical synthesis and biological testing of potential type II kinase inhibitors.","volume":"3","author":"G Schneider","year":"2011","journal-title":"Future Med Chem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1021\/ci800215t","article-title":"Reaction-MQL: line notation for functional transformation.","volume":"49","author":"FH Reisen","year":"2009","journal-title":"J Chem Inf Model"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1021\/ci049714+","article-title":"ZINC - a free database of commercially available compounds for virtual screening.","volume":"45","author":"JJ Irwin","year":"2005","journal-title":"J Chem Inf Model"},{"key":"ref17","article-title":"ZINC database."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1021\/ci990423o","article-title":"Strategic pooling of compounds for high-throughput screening.","volume":"39","author":"M Hann","year":"1999","journal-title":"J Chem Inf Comput Sci"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1021\/ci700274r","article-title":"Kernel approach to molecular similarity based on iterative graph similarity.","volume":"47","author":"M Rupp","year":"2007","journal-title":"J Chem Inf Model"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cmdc.200900469","article-title":"From machine learning to natural product derivatives that selectively activate transcription factor PPARgamma.","volume":"5","author":"M Rupp","year":"2010","journal-title":"ChemMedChem"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/A:1008068904628","article-title":"Feature trees: a new molecular similarity measure based on tree matching.","volume":"12","author":"M Rarey","year":"1998","journal-title":"J Comput Aided Mol Des"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1021\/c160040a013","article-title":"Mathematical basis of ring-finding algorithms at CIDS.","volume":"11","author":"M Plotkin","year":"1971","journal-title":"J Chem Doc"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1021\/ci025584y","article-title":"The Chemistry Development Kit (CDK): an open-source Java library for chemo- and bioinformatics.","volume":"43","author":"C Steinbeck","year":"2003","journal-title":"J Chem Inf Comput Sci"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2174\/138161206777585274","article-title":"Recent developments of the Chemistry Development Kit (CDK) - an open-source Java library for chemo- and bioinformatics.","volume":"12","author":"C Steinbeck","year":"2006","journal-title":"Curr Pharm Des"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.","volume":"23","author":"CA Lipinski","year":"1997","journal-title":"Adverse Drug Deliver Rev"},{"key":"ref26","first-page":"341","article-title":"Navigation in chemical space: ligand-based design of focused compound libraries.","author":"G Schneider","year":"2005"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1023\/A:1016024005429","article-title":"Lipophilicity in molecular modeling.","volume":"13","author":"B Testa","year":"1996","journal-title":"Pharm Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/cr60274a001","article-title":"Partition coefficients and their uses.","volume":"71","author":"A Leo","year":"1971","journal-title":"Chem Rev"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/minf.201000019","article-title":"Bioisosteric replacement and scaffold hopping in lead generation and optimization.","volume":"29","author":"SR Langdon","year":"2010","journal-title":"Mol Inf"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1074\/mcp.T400003-MCP200","article-title":"Trypsin cleaves exclusively C-terminal to arginine and lysine residues.","volume":"3","author":"JV Olsen","year":"2004","journal-title":"Mol Cell Proteomics"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.tips.2010.05.007","article-title":"Exploring the chemical space of gamma-secretase modulators.","volume":"31","author":"H Zettl","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd2896","article-title":"Alzheimer&apos;s disease: strategies for disease modification.","volume":"9","author":"M Citron","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","article-title":"A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.","volume":"414","author":"S Weggen","year":"2001","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1021\/jm1003073","article-title":"Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity.","volume":"53","author":"M Hieke","year":"2010","journal-title":"J Med Chem"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nm1235","article-title":"Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production.","volume":"11","author":"T Kukar","year":"2005","journal-title":"Nat Med"},{"key":"ref36","first-page":"103","article-title":"Drug discovery: from hits to vlinical vandidates.","author":"S Celanire","year":"2009"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1517\/14728220903188438","article-title":"Histamine H<sub>3<\/sub> and H<sub>4<\/sub> receptors as novel drug targets.","volume":"18","author":"E Tiligada","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1021\/jm7014217","article-title":"Fragment based design of new H<sub>4<\/sub> receptor-ligands with anti-inflammatory properties in vivo.","volume":"51","author":"RA Smits","year":"2008","journal-title":"J Med Chem"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cmdc.200800443","article-title":"Homology model adjustment and ligand screening with a pseudoreceptor of the human histamine H<sub>4<\/sub> receptor.","volume":"4","author":"Y Tanrikulu","year":"2009","journal-title":"ChemMedChem"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"7186","DOI":"10.1016\/j.bmc.2009.08.059","article-title":"2,4-Diaminopyrimidines as histamine H<sub>4<\/sub> receptor ligands \u2013 scaffold optimization and pharmacological characterization.","volume":"17","author":"K Sander","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1016\/j.bmcl.2006.08.117","article-title":"Identification of 2-arylbenzimidazoles as potent human histamine H<sub>4<\/sub> receptor ligands.","volume":"16","author":"A Lee-Dutra","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1021\/bi802050d","article-title":"High constitutive activity and a G-protein-independent high-affinity state of the human histamine H<sub>4<\/sub>-receptor.","volume":"48","author":"EH Schneider","year":"2009","journal-title":"Biochemistry"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bmcl.2008.09.012","article-title":"Potential utility of histamine H<sub>3<\/sub> receptor antagonist pharmacophore in antipsychotics.","volume":"19","author":"Y von Coburg","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/cbic.201000180","article-title":"In silico characterization of different ligand binding modes in the human histamine H<sub>4<\/sub> receptor and their impact on receptor activation.","volume":"11","author":"T Werner","year":"2010","journal-title":"ChemBioChem"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/jm00014a003","article-title":"New orally active serine protease inhibitors.","volume":"38","author":"K Senokuchi","year":"1995","journal-title":"J Med Chem"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/14756369509040684","article-title":"The X-ray crystal structure of thrombin in complex with N-alpha-2-naphthylsulfonyl-L-3-amidino-phenylalanyl-4-methylpiperidide: the beneficial effect of filling out an empty cavity.","volume":"9","author":"A Bergner","year":"1995","journal-title":"J Enzyme Inhib"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/jm0303857","article-title":"In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1&apos; subsite and its implications to structure-based drug design.","volume":"48","author":"MJ Costanzo","year":"2005","journal-title":"J Med Chem"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1254\/fpj.91.285","article-title":"Effects of E-3123, a new protease inhibitor, on several protease activities and on experimental acute pancreatitis.","volume":"91","author":"K Miyamoto","year":"1988","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1248\/cpb.37.2855","article-title":"Kinetic study on the mechanism of inhibition of trypsin and trypsin-like enzymes by <italic>p<\/italic>-guanidinobenzoate ester.","volume":"37","author":"S Nochi","year":"1998","journal-title":"Chem Pharm Bull"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/13543784.8.9.1373","article-title":"Direct thrombin inhibitors: current status and future prospects.","volume":"8","author":"K Menear","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0960-894X(03)00030-1","article-title":"Novel thrombin inhibitors incorporating non-basic partially saturated heterobicyclic P1-Arginine mimetics.","volume":"13","author":"L Peterlin-Masic","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1021\/jm970493r","article-title":"Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position.","volume":"40","author":"DM Feng","year":"1997","journal-title":"J Med Chem"},{"key":"ref53","first-page":"11","article-title":"Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators.","volume":"20","author":"A Rivkin","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1124\/jpet.103.061754","article-title":"A potent and selective histamine H<sub>4<\/sub> receptor antagonist with anti-inflammatory properties.","volume":"309","author":"RL Thurmond","year":"2004","journal-title":"J Pharm Exp Ther"}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1002380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T20:55:29Z","timestamp":1540328129000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1002380"}},"subtitle":[],"editor":[{"given":"James M.","family":"Briggs","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,2,16]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,2,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1002380","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,16]]}}}